Abstract Details

Title Person-centered Assessment in Early Alzheimer's Disease

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 003

Objective

The aim of this study was to assess the perception of quality of life (QoL) in patients with early AD using a battery of patient-reported measurements.

Background Limited information is available on patients´ experience living with Alzheimer´s disease (AD) at earlier stages.

Design/Methods A non-interventional, cross-sectional study was conducted in 21 memory clinics. Patients 50-90 years of age, diagnosed with mild or prodromal AD (NIA/AA criteria), a Mini-mental State Examination (MMSE) score ≥ 22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5 or 1.0 were included.

The QoL in Alzheimer Disease Scale (QoL-AD), AD Assessment Scale- Cognition-Subscale 13 (ADAS-Cog13), Representations and Adjustment to Dementia Index (RADIX), Beck Depression Inventory - Fast Screen (BDI-FS), Stigma Scale for Chronic Illness (SSCI-8), General Self-Efficacy Scale (GSES), and Beck Hopelessness Scale (BHS) were used to gather information on QoL, cognition, illness representations, mood, stigmatization, self-efficacy, and hopelessness, respectively. Correlations between QoL-AD and other outcome measures were examined.

Results

A total of 149 patients were included. Mean age (SD) was 72.3 ± 7.0 years and 50.3% were female. Mean disease duration was 1.3 ± 1.7 years. Mean MMSE score was 24.6 ± 2.1, mean ADAS-Cog13 score was 24.4 ± 5.2, and 87.2% had a CDR-GS score of 0.5. The mean QoL-AD score was 37.9 ± 4.5. Stigma prevalence was 37% (n=55). 22.1% of patients (n=33) showed depressive symptoms and mild-to-moderate hopelessness was found in 94% (n=139). The QoL-AD score showed a significant positive correlation with GSES score (rho=0.345, p<0.0001) and negative correlations with BDI-FS score (rho= -0.458, p<0.0001), SSCI-8 score (rho=-0.319, p<0.0001), practical (rho=-0.389) and emotional (rho=-0.413) [p<0.0001] consequences RADIX scores, and BHS score (rho=-0.222, p=0.006).

Conclusions A better understanding of patients´ perspectives and concerns at earlier stages of AD may facilitate implementing individualized supporting strategies to improve QoL.

Authors/Disclosures
Alberto Villarejo Galende PRESENTER	Alberto Villarejo Galende has nothing to disclose.
	No disclosure on file
Gerard Pinol-Ripoll	No disclosure on file
	No disclosure on file
Felix Vinuela, MD	Felix Vinuela, MD has nothing to disclose.
Mercè Boada Rovira, MD, PhD (Fundació ACE. Institut Català de Neurociènces Aplicades)	Dr. Boada Rovira has received personal compensation for serving as an employee of FUNDACIO ACE. ICNA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LILLY. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVO NORDISK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOIBERICA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SERVIER. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SCHWABE PHARMA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NUTRICIA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SERVIER. Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for ZAMBON.
	No disclosure on file
	No disclosure on file
Mario Riverol, MD (Clinica Universitaria Navarra)	No disclosure on file
	No disclosure on file
	No disclosure on file
Rafael Arroyo Gonzalez	Rafael Arroyo Gonzalez has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Eloy Rodriguez-Rodriguez (Hospital Marques De Valdecilla)	Eloy Rodriguez-Rodriguez has nothing to disclose.
	No disclosure on file
Guillermo Garcia-Ribas, MD	Dr. Garcia-Ribas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocross. Dr. Garcia-Ribas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Garcia-Ribas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Esteve. Dr. Garcia-Ribas has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Nutricia. Dr. Garcia-Ribas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Garcia-Ribas has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alter. Dr. Garcia-Ribas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuraxpharm. The institution of Dr. Garcia-Ribas has received research support from Instituto de Investigación Ramón y Cajal. Dr. Garcia-Ribas has received personal compensation in the range of $50,000-$99,999 for serving as a Physician with Hospital Universitario Ramón y Cajal, IMSALUD.
	No disclosure on file
Alberto Lleo, MD (Hospital De La Santa Creu I Sant Pau)	Dr. Lleo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lleo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Lleo has received research support from Instituto de Salud Carlos III. The institution of Dr. Lleo has received research support from Generalitat de Calalunya (PERIS). The institution of Dr. Lleo has received research support from BBVA Foundation. The institution of Dr. Lleo has received research support from La Caixa Foundation. Dr. Lleo has received intellectual property interests from a discovery or technology relating to health care.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132)	Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
	No disclosure on file
Jorge Maurino	Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.

��ɫ��

��ɫ��